Cargando…
Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer
BET (bromodomain and extra-terminal) proteins regulate gene expression through their ability to bind to acetylated chromatin and subsequently activate RNA PolII-driven transcriptional elongation. Small molecule BET inhibitors prevent binding of BET proteins to acetylated histones and inhibit transcr...
Autores principales: | Wyce, Anastasia, Degenhardt, Yan, Bai, Yuchen, Le, BaoChau, Korenchuk, Susan, Crouthamel, Ming-Chih, McHugh, Charles F., Vessella, Robert, Creasy, Caretha L., Tummino, Peter J., Barbash, Olena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3926837/ https://www.ncbi.nlm.nih.gov/pubmed/24293458 |
Ejemplares similares
-
BET Inhibition Silences Expression of MYCN and BCL2 and Induces Cytotoxicity in Neuroblastoma Tumor Models
por: Wyce, Anastasia, et al.
Publicado: (2013) -
MEK inhibitors overcome resistance to BET inhibition across a number of solid and hematologic cancers
por: Wyce, Anastasia, et al.
Publicado: (2018) -
Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition
por: Mao, Wendy, et al.
Publicado: (2019) -
Selective inhibition of BET bromodomains
por: Filippakopoulos, Panagis, et al.
Publicado: (2010) -
Therapeutic Targeting of BET Bromodomain Proteins in Castration-Resistant Prostate Cancer
por: Asangani, Irfan A., et al.
Publicado: (2014)